(NEW YORK) — The cash price for popular weight-loss medications Wegovy and and the medication authorized for people with type 2 diabetes Ozempic are dropping by 30% in U.S. on Monday, according to Novo Nordisk, the Danish pharmaceutical company that manufactures both drugs.

The new monthly cost for either GLP-1 drug will be $349, down from its current price of $499, for customers who are not using insurance, the company said. The new pricing will be in place on Monday at 70,000 retail pharmacies and other places, including Walmart and Costco’s pharmacies, the drugmaker said.

The previous cash price for Wegovy matched that of a full dose of Zepbound, a competing drug from competitor Eli Lilly.

“As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy an

See Full Page